Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA accepts Stemline Therapeutics' IND for phase II trial of SL-701 for GBM

April 11, 2014

AVEO Oncology and Biodesix partner on development of ficlatuzumab and companion diagnostic test

April 11, 2014

JNJ-61186372 demonstrates activity for the treatment EGFR/c-Met-aberrant malignancies

April 8, 2014

IGM-55.5 potently binds and kills B cells in NHL patients

April 8, 2014

Clinical study evaluates immunological response EMD-640744 in solid tumors

April 8, 2014

New START2 trial investigates tecemotide in stage III NSCLC

April 7, 2014

MT-3724 shows significant antitumor activity in vitro and in vivo

April 7, 2014

Amgen reports topline results from phase III study of talimogene laherparepvec

April 7, 2014

GSK ends MAGRIT study of MAGE-A3 cancer immunotherapeutic

April 2, 2014

RG-7813 enters first clinical trial for cancer

March 31, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.